https://www.selleckchem.com/pr....oducts/pexidartinib-
Data analysis was performed using monthly statistical process control charts. We achieved 62.6% (n=885/1426) for BP140/90 and 24.47% (n=349/1426) for BP130/80 within 12 months project period. We sustained and exceeded at 72.64% (n=945/1301) for BP140/90 and 44.58% (n=580/1301) for BP130/80 during the 10 months post-project period. Overcoming physician clinical inertia, enhancing patient adherence to appointments and medications, and a high functioning multidisciplinary team were the key drivers for the succe
Like
Comment
Share
